Two of Britain's leading science innovators – Mab specialist Kymab Ltd. and GPCR-targeting Heptares Therapeutics – are joining forces to discover, develop and commercialize new antibody drugs targeting a number of G protein-coupled receptors, focusing initially on immuno-oncology.
GPCRs are widely expressed on cells of the innate and adaptive immune system and play key roles in modulating cell migration and recruitment to the tumour environment, activation, survival, proliferation and differentiation